Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) announced a quarterly dividend on Wednesday, August 12th. Stockholders of record on Tuesday, October 6th will be given a dividend of 0.86 per share by the medical research company on Wednesday, October 21st. This represents a c) annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th.
Quest Diagnostics has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 14 years. Quest Diagnostics has a payout ratio of 32.7% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Quest Diagnostics to earn $11.95 per share next year, which means the company should continue to be able to cover its $3.44 annual dividend with an expected future payout ratio of 28.8%.
Quest Diagnostics Stock Up 0.0%
Shares of DGX opened at $237.53 on Thursday. The firm has a market capitalization of $26.22 billion, a P/E ratio of 25.22, a P/E/G ratio of 2.19 and a beta of 0.56. Quest Diagnostics has a 12-month low of $171.18 and a 12-month high of $240.13. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The firm has a fifty day moving average price of $214.12 and a 200-day moving average price of $202.57.
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Read More
- Five stocks we like better than Quest Diagnostics
- Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
